

# Pharmacy Practice

This Act comprehensively updates and also expands the laws governing the practice of pharmacy in the state, by individual pharmacists, retail pharmacies, and health care systems in the state. It requires out-of-state pharmacies doing business in this State to register with the state, and meet certain other public safety and consumer-oriented requirements. Perhaps most significantly, the Act expands the authorized practice of pharmacy to include collaborative drug therapy management, a cooperative agreement between a doctor and a pharmacist, with the patient's consent, in which the pharmacist may take a more active role in the management of the patient's prescription drug therapy than is currently permissible. The bill also codifies the role of the pharmacist technician and defines the activities that may be performed by pharmacy technicians.

Submitted as:

New Jersey

Chapter 280

Status: Enacted into law in 2004.

## Suggested State Legislation

(Title, enacting clause, etc.)

1           Section 1. [*Short Title.*] This Act shall be known and may be cited as “The Pharmacy  
2 Practice Act.”

3

4           Section 2. [*Legislative Findings.*]

5           a. The practice of pharmacy in this State is declared a health care professional practice  
6 affecting the public health, safety and welfare and is subject to regulation and control in the  
7 public interest. It is further declared to be a matter of public interest and concern that the practice  
8 of pharmacy merits and receives the confidence of the public and that only qualified persons be  
9 permitted to engage in the practice of pharmacy in this State. This Act shall be liberally  
10 construed to carry out these objectives and purposes.

11           b. It is the purpose of this Act to promote, preserve and protect the public health, safety  
12 and welfare by and through the effective control and regulation of the practice of pharmacy, the  
13 licensure of pharmacists and the permitting, control and regulation of all pharmacy practice sites  
14 in this State that engage in the practice of pharmacy.

15

16           Section 3. [*Definitions Relative to Pharmacists.*] As used in this Act:

17           “Administer” means the direct application of a drug to the body of a patient or research  
18 subject by subcutaneous, intramuscular or intradermal injection, inhalation or ingestion by a  
19 pharmacist engaged in collaborative practice or in accordance with regulations jointly  
20 promulgated by the [board] and the [State Board of Medical Examiners].

21           “Automated medication device” means a discrete unit that performs specific drug  
22 dispensing operations.

23           “Automated medication system” means any process that performs operations or  
24 activities, other than compounding or administration, relative to the storage, packaging,  
25 dispensing and distribution of medications and which collects, controls and maintains all  
26 transaction information.

27 “Board of Pharmacy” or “board” means the [State Board of Pharmacy].

28 “Certification” means a certification awarded by a recognized non-government specialty  
29 organization to signify that a pharmacist has met predetermined qualifications and to signify to  
30 the public that the pharmacist is competent to practice in the designated specialty.

31 “Collaborative drug therapy management” means a written protocol directed on a  
32 voluntary basis by a patient’s physician, with the patient’s consent, that is between a patient’s  
33 physician who is treating the patient for a specific disease and a pharmacist for cooperative  
34 management of a patient’s drug, biological and device-related health care needs, which shall be  
35 conducted in accordance with regulations jointly promulgated by the [board] and the [State  
36 Board of Medical Examiners] and shall only include the collecting, analyzing and monitoring of  
37 patient data; ordering or performing of laboratory tests based on the standing orders of a  
38 physician as set forth in the written protocol; ordering of clinical tests based on the standing  
39 orders of a physician as set forth in the written protocol, provided those laboratory tests are  
40 granted waived status in accordance with the provisions of the [insert citation], and are for the  
41 treatment of a disease state identified jointly by the board and the [State Board of Medical  
42 Examiners] as subject to collaborative drug therapy management; modifying, continuing or  
43 discontinuing drug or device therapy; and therapeutic drug monitoring with appropriate  
44 modification to dose, dosage regimen, dosage forms or route of administration. The  
45 interpretation of clinical or laboratory tests under a written protocol may only be performed by a  
46 pharmacist in direct consultation with a physician.

47 “Compounding” means the preparation, mixing, assembling, packaging or labeling of a  
48 drug or device as the result of a practitioner’s prescription or initiative based on the relationship  
49 of the practitioner or patient with the pharmacist in the course of professional practice or for the  
50 purpose of, or incident to, research, teaching or chemical analysis and not for sale or dispensing.  
51 Compounding also includes the preparation of drugs or devices in anticipation of prescription  
52 drug orders based on routine, regularly observed prescribing patterns. Nothing in this Act is  
53 meant to limit a prescriber’s ability under pre-existing law to order a compounded medication for  
54 use in the prescriber’s practice, as permitted by State and federal law.

55 “Confidential information” means information that is identifiable as to the patient  
56 involved that a pharmacist accesses, transmits or maintains in a patient’s record or which is  
57 communicated to or by the patient as part of patient counseling.

58 “Credentialing” means the process by which an approved academic institution awards a  
59 certificate to signify that the credentialed pharmacist has completed the required courses,  
60 examinations or both, that indicate advanced knowledge of a particular area of pharmacy.

61 “Deliver” or “delivery” means the actual, constructive or attempted transfer of a drug or  
62 device from one person to another, whether or not for consideration.

63 “Device” means an instrument, apparatus, implement, machine, contrivance, implant or  
64 other similar or related article, including any component part or accessory, which is required  
65 under federal law to bear the label “RX Only.”

66 “Dispense” or “dispensing” means the procedure entailing the interpretation of a  
67 practitioner’s prescription order for a drug, biological or device, and pursuant to that order the  
68 proper selection, measuring, compounding, labeling and packaging in a proper container for  
69 subsequent administration to, or use by, a patient.

70 “Dosage form” means the physical formulation or medium in which the product is  
71 intended, manufactured and made available for use, including, but not limited to: tablets,  
72 capsules, oral solutions, aerosols, inhalers, gels, lotions, creams, ointments, transdermals and  
73 suppositories, and the particular form of the above which utilizes a specific technology or  
74 mechanism to control, enhance or direct the release, targeting, systemic absorption or other  
75 delivery of a dosage regimen in the body.

76 “Drug or medication” means articles recognized as drugs in any official compendium, or  
77 supplement thereto, designated from time to time by the board for use in the diagnosis, cure,  
78 mitigation, treatment or prevention of disease in humans or other animals; articles intended for  
79 use in the diagnosis, cure, mitigation, treatment or prevention of disease in humans or other  
80 animals; articles intended to affect the structure or any function of the body of humans or other  
81 animals, except that a food, dietary ingredient or dietary supplement, as those terms are defined  
82 in 21 U.S.C.s.321, is not a drug solely because the label or the labeling contains such a claim;  
83 and articles intended for use as a component of and articles specified in this definition of “drug  
84 or medication.”

85 “Drug utilization review” includes, but is not limited to, the following activities:

86 (1) Evaluation of prescription drug orders and patient records for known allergies,  
87 rational therapy-contraindications, appropriate dose and route of administration and appropriate  
88 directions for use;

89 (2) Evaluation of prescription drug orders and patient records for duplication of  
90 therapy;

91 (3) Evaluation of prescription drug orders and patient records for interactions  
92 between drug-drug, drug-food, drug-disease and adverse drug reactions; and

93 (4) Evaluation of prescription drug orders and patient records for proper  
94 utilization, including over- or under-utilization, and optimum therapeutic outcomes.

95 “Extern” means any person who is in the [fifth or sixth year] of college or the [third or  
96 fourth professional year], at an accredited school or college of pharmacy approved by the  
97 [board], who is assigned to a training site for the purpose of acquiring accredited practical  
98 experience under the supervision of the school or college at which the person is enrolled.

99 “Electronic means” means any electronic or digital transmission format, including  
100 facsimile or computer generated messaging.

101 “Immediate supervision” means a level of control which assures that the pharmacist is  
102 physically present at the pharmacy practice site and has the responsibility for accuracy and safety  
103 with respect to the actions of pharmacy technicians, interns and externs.

104 “Intern” means any person who has graduated from an accredited school or college of  
105 pharmacy approved by the [board], or if a foreign pharmacy graduate, any person who has met  
106 all of the requirements of the [board], and who is being trained by an approved preceptor for the  
107 purpose of acquiring accredited practical experience and who has first registered for that purpose  
108 with the [board].

109 “Labeling” means the process of preparing and affixing a label to any drug container,  
110 exclusive however, of the labeling by a manufacturer, packer or distributor of a non-prescription  
111 drug or commercially packaged legend drug or device.

112 “Licensure” means the process by which the [board] grants permission to an individual  
113 to engage in the practice of pharmacy upon finding that the applicant has attained the degree of  
114 competency necessary to ensure that the public health, safety and welfare will be protected.

115 “Medication error” means a preventable event that may cause or lead to inappropriate  
116 use of a medication or patient harm while the medication is in the control of the practitioner,  
117 patient or consumer.

118 “Medication order” means a prescription for a specific patient in an institutional setting.

119 “Modifying” means to change a specific drug, the dosage, or route of delivery of a drug  
120 currently being administered for an existing diagnosis pursuant to a collaborative drug therapy  
121 management.

122 “Non-prescription drug or device” means a drug or device which may be obtained  
123 without a prescription and which is labeled for consumer use in accordance with the  
124 requirements of the laws and rules of this State and the federal government.

125 “Permit” means the authorization granted by the [board] to a site to engage in the  
126 practice of pharmacy.

127 “Person” means an individual, corporation, partnership, association or any other legal  
128 entity including government.

129 “Pharmaceutical care” means the provision by a pharmacist of drug therapy review and  
130 other related patient care services intended to achieve positive outcomes related to the treatment,  
131 cure or prevention of a disease; control, elimination or reduction of a patient’s symptoms; or  
132 arresting or slowing of a disease process as defined by the rules and regulations of the [board].

133 “Pharmacist” means an individual currently licensed by this State to engage in the  
134 practice of pharmacy.

135 “Pharmacist-in-charge” means a pharmacist who accepts responsibility for the operation  
136 of a pharmacy practice site in conformance with all laws and rules pertinent to the practice of  
137 pharmacy and the distribution of drugs.

138 “Pharmacist in collaborative practice” means a pharmacist engaged in the collaborative  
139 drug therapy management of a patient’s drug, biological and device-related health care needs  
140 pursuant to a written protocol, in collaboration with a licensed physician and in accordance with  
141 the regulations jointly promulgated by the [board] and the [State Board of Medical Examiners].

142 “Pharmacy practice site” means any place in this State where drugs are dispensed or  
143 pharmaceutical care is provided by a licensed pharmacist, but shall not include a medical office  
144 under the control of a licensed physician.

145 “Pharmacy technician” means an individual working in a pharmacy practice site who,  
146 under the immediate supervision of a pharmacist, assists in pharmacy activities as permitted by  
147 this section of this Act and the rules and regulations of the [board] that do not require the  
148 professional judgment of a pharmacist.

149 “Practice of pharmacy” means a health care service by a pharmacist that includes:  
150 compounding, dispensing and labeling of drugs, biologicals, radio pharmaceuticals or devices;  
151 overseeing automated medication systems; interpreting and evaluating prescriptions;  
152 administering and distributing drugs, biologicals and devices; maintaining prescription drug  
153 records; advising and consulting on the therapeutic values, content, hazards and uses of drugs,  
154 biologicals and devices; managing and monitoring drug therapy; collecting, analyzing and  
155 monitoring patient data; performing drug utilization reviews; storing prescription drugs and  
156 devices; supervising technicians, interns and externs; and such other acts, services, operations or  
157 transactions necessary, or incidental to, providing pharmaceutical care and education. In  
158 accordance with written guidelines or protocols established with a licensed physician, the  
159 “practice of pharmacy” also includes collaborative drug therapy management including  
160 modifying, continuing or discontinuing drug or device therapy; ordering or performing of  
161 laboratory tests under collaborative drug therapy management; and ordering clinical tests,  
162 excluding laboratory tests, unless those tests are part of collaborative drug therapy management.

163 “Practitioner” means an individual currently licensed, registered or otherwise authorized  
164 by the jurisdiction in which the individual practices to administer or prescribe drugs in the course  
165 of professional practice.

166 “Preceptor” means an individual who is a pharmacist, meets the qualifications under the  
167 rules and regulations of the [board], and participates in the instructional training of pharmacy  
168 interns and externs.

169 “Prescription” means a lawful order of a practitioner for a drug, a device or diagnostic  
170 agent for a specific patient.

171 “Prescription drug” or “legend drug” means a drug which, under federal law, is required  
172 to be labeled prior to being delivered to the pharmacist, with either of the following statements:  
173 “Rx Only” or “Caution: Federal law restricts this drug to use by, or on the order of, a licensed

174 veterinarian” or is required by any applicable federal or state law, rule or regulation to be  
175 dispensed pursuant to a prescription drug order or is restricted to use by a practitioner only.

176 “Registration” means the process of making a list or being enrolled in an existing list.

177 “Therapeutic interchange” means the substitution and dispensing of a drug chemically  
178 dissimilar from the prescription drug originally prescribed.

179

180 Section 4. [*Powers, Duties, Authority of Board.*]

181 The [board] shall enforce the provisions of this Act. The [board] shall have all of the  
182 duties, powers and authority specifically granted by or necessary for the enforcement of this Act,  
183 as well as such other duties, powers and authority as it may be granted from time to time by  
184 applicable law.

185

186 Section 5. [*Board Membership, Terms, Vacancies.*]

187 a. The [board] shall consist of [eleven members], [two] of whom shall be public members  
188 and one of whom shall be a [State executive department] member appointed pursuant to the  
189 provisions of [insert citation]. Each of the remaining [eight] members shall be pharmacists. Each  
190 pharmacist member shall have at least [five years] of experience in the practice of pharmacy in  
191 this State after licensure, and shall at the time of appointment and throughout their tenure: be  
192 currently licensed and in good standing to engage in the practice of pharmacy in this State, and  
193 be actively engaged in the practice of pharmacy in this State.

194 b. The [Governor] shall appoint the members of the [board]. Every State professional  
195 pharmacy association may send to the [Governor] the names of pharmacists having the  
196 qualifications required by this section, whom the [Governor] may appoint to fill any vacancy  
197 occurring in the [board]. In appointing members to the [board] to fill vacancies of members who  
198 engage in the practice of pharmacy, the [Governor] shall appoint members so that the  
199 membership of the [board] includes, at all times, at least [one pharmacist] employed by a chain  
200 drug retailer who owns or operates [seven] or more pharmacy practice sites, [one pharmacist]  
201 who is employed by a health care system and [one pharmacist] who owns a pharmacy practice  
202 site in this State.

203 c. Except for the members first appointed, members of the [board] shall be appointed for  
204 a term of [five years], except that members of the [board] who are appointed to fill vacancies  
205 which occur prior to the expiration of a former member’s full term shall serve the unexpired  
206 portion of that term. The terms of the members of the [board] shall be staggered, so that the  
207 terms of no more than [three] members shall expire in any year. Each member shall serve until a  
208 successor is appointed and qualified. The present members of the [board] appointed pursuant to  
209 [insert citation] shall serve the balance of their terms. Any present [board] member appointed  
210 initially for a term of less than [five years] shall be eligible to serve for [two additional] full  
211 terms. No member of the [board] shall serve more than [two consecutive] full terms. The  
212 completion of the unexpired portion of a full term shall not constitute a full term for purposes of  
213 this subsection.

214 d. The [Governor] may remove a member of the [board] after a hearing for misconduct,  
215 incompetency, neglect of duty or for any other sufficient cause.

216

217 Section 6. [*Election of Officers.*]

218 a. The [board] shall annually elect from among its members a [president] and [vice-  
219 president].

220 b. The position of [executive director] shall be held by a pharmacist licensed in this  
221 State. The [executive director] shall be responsible for the performance of the administrative  
222 functions of the [board] and those other duties that the [board] may direct.

223  
224  
225  
226  
227  
228  
229  
230  
231  
232  
233  
234  
235  
236  
237  
238  
239  
240  
241  
242  
243  
244  
245  
246  
247  
248  
249  
250  
251  
252  
253  
254  
255  
256  
257  
258  
259  
260  
261  
262  
263  
264  
265  
266  
267  
268  
269  
270

Section 7. [*Compensation.*] Each member of the [board] shall receive compensation pursuant to [insert citation] of [\$150] per day for each day on which the member is engaged in performance of the official duties of the [board], and shall be reimbursed for all reasonable and necessary expenses incurred in connection with the discharge of those official duties.

Section 8. [*Board Meetings.*] The [board] shall meet at least [once] every month to transact its business. The [board] shall meet at those additional times that it may determine. Additional meetings may be called by the [president of the board] or by [two-thirds] of the members of the [board].

Section 9. [*Rules, Regulations; Joint Rules.*] The [board] shall make, adopt, amend and repeal those rules and regulations necessary for the proper administration and enforcement of this act. Those rules and regulations shall be promulgated in accordance with the [insert citation]. Rules pertaining to collaborative drug therapy management and administration of drugs by pharmacists shall be jointly promulgated by the board and the [State Board of Medical Examiners].

Section 10. [*Responsibilities of Board.*]

a. The [board] shall be responsible for the control and regulation of the practice of pharmacy in this State including, but not limited to, the following:

- (1) The licensing by examination or by license transfer of applicants who are qualified to engage in the practice of pharmacy under the provisions of this Act;
- (2) The renewal of licenses to engage in the practice of pharmacy;
- (3) The establishment and enforcement of professional standards and rules of conduct of pharmacists engaged in the practice of pharmacy;
- (4) The establishment of requirements for pharmacists to engage in collaborative practice;
- (5) The establishment of requirements jointly promulgated with the [State Board of Medical Examiners] for pharmacists to administer drugs directly to patients;
- (6) The enforcement of those provisions of this Act relating to the conduct or competence of pharmacists practicing in this State, and the suspension, revocation, failure to renew or restriction of licenses to engage in the practice of pharmacy pursuant to the provisions of [insert citation];
- (7) The regulation of pharmacy practiced through any technological means;
- (8) The regulation and control of automated medication systems and automated medication devices within or outside of pharmacy practice sites;
- (9) The right to seize any drugs and devices found by the [board] to constitute an imminent danger to the public health and welfare;
- (10) The establishment of minimum specifications for record keeping, prescription and patient profile record maintenance, pharmacy practice sites including, but not limited to, the physical premises, technical equipment, environment, supplies, personnel and procedures for the storage, compounding and dispensing of drugs or devices, and for the monitoring of drug therapy;
- (11) The inspection of any pharmacy practice site at all reasonable hours for the purpose of determining if any provisions of the laws governing the legal distribution of drugs or devices or the practice of pharmacy are being violated. The [board], its officers, inspectors and representatives shall cooperate with all agencies charged with the enforcement of the laws of the

271 United States, of this State, and of all other states relating to drugs, devices and the practice of  
272 pharmacy;

273 (12) The inspection of prescription files and the prescription records of a  
274 pharmacy and the removal from the files and taking possession of any original prescription,  
275 providing that the authorized agent removing or taking possession of an original prescription  
276 shall place in the file from which it was removed a copy certified by that person to be a true copy  
277 of the original prescription removed; provided further, that the original copy shall be returned by  
278 the [board] to the file from which it was removed after it has served the purpose for which it was  
279 removed;

280 (13) The establishment of requirements for patient counseling, patient profiles and  
281 drug utilization reviews;

282 (14) The establishment of regulations to protect the health and safety of pharmacy  
283 patients; and

284 (15) The prescribing or changing of the fees for examinations, certifications,  
285 licensures, renewals and other services performed pursuant to [insert citation] and this Act.

286 b. The [board] shall have those other duties, powers and authority as may be necessary to  
287 the enforcement of this Act and to the enforcement of rules and regulations of the [board], which  
288 may include, but not be limited to, the following:

289 (1) The determination and issuance of standards, recognition and approval of  
290 degree programs of schools and colleges of pharmacy whose graduates shall be eligible for  
291 licensure in this State, and the specifications and enforcement of requirements for practical  
292 training, including internships;

293 (2) The registration of externs, interns, pharmacy preceptors and pharmacy  
294 technicians;

295 (3) The regulation of the training, qualifications and conduct of applicants,  
296 externs, interns, pharmacy preceptors and pharmacy technicians;

297 (4) The collection of professional demographic data;

298 (5) The joining with those professional organizations and associations organized  
299 to promote the improvement of the standards of the practice of pharmacy for the protection of the  
300 health and welfare of the public or whose activities assist and facilitate the work of the [board];

301 (6) The establishment of a bill of rights for patients concerning the health care  
302 services a patient may expect in regard to pharmaceutical care;

303 (7) The engagement in activities to educate consumers, to assist them in obtaining  
304 information necessary to make decisions about medication issues;

305 (8) The establishment of standards for the continuing education of registered  
306 pharmacists;

307 (9) The establishment of rules and regulations for extraordinary emergency  
308 situations that interfere with the ability to practice under the current rules and regulations;

309 (10) The establishment of guidelines for [board] approved pilot programs. The  
310 guidelines shall be complied with to implement a program that may not be presently  
311 acknowledged in this act or its rules or regulations; and

312 (11) The assurance that any credentialing or certification of a pharmacist is not  
313 misleading to the public.

314 c. (1) The [board] may place under seal all drugs, biologicals, radio pharmaceuticals  
315 or devices that are owned by or in the possession, custody or control of a licensee or permit  
316 holder at the time his license or permit is suspended or revoked or at the time the board refused  
317 to renew his license. Except as otherwise provided in this section, drugs, biologicals, radio  
318 pharmaceuticals or devices that are sealed pursuant to this paragraph shall not be disposed of  
319 until appeal rights under the [insert citation] have expired, or an appeal filed pursuant to that act

320 has been determined. The court, involved in an appeal filed pursuant to the [insert citation], may  
321 order the [board], during the pendency of the appeal, to sell sealed drugs, biologicals and radio  
322 pharmaceuticals that are perishable. The proceeds of a sale shall be deposited with the court.

323 (2) Notwithstanding any provisions of this Act to the contrary, whenever a duly  
324 authorized representative of the [board] finds, or has probable cause to believe, that any drug or  
325 device is outdated, adulterated or misbranded within the meaning of the “Federal Food, Drug,  
326 and Cosmetic Act,” 21 U.S.C.s.301 et seq., the representative shall affix to that drug or device a  
327 tag or other appropriate marking giving notice that the article is or is suspected of being  
328 outdated, adulterated or misbranded, had been detained or embargoed, and warning all persons  
329 not to remove or dispose of the article by sale or otherwise until provision for removing or  
330 disposal is given by the [board], its agent or the court. No person shall remove or dispose of an  
331 embargoed drug or device by sale or otherwise without the permission of the [board] or its agent  
332 or, after summary proceedings have been instituted, without permission of the court.

333 (3) When a drug or device detained or embargoed under paragraph (2) of this  
334 subsection c. of this section has been declared by the representative to be outdated, adulterated or  
335 misbranded, the [board] shall, as soon as practical thereafter, petition the judge of the court in  
336 which jurisdiction the article is detained or embargoed for an order for condemnation of that  
337 article. If the judge determines that this drug or device so detained or embargoed is not  
338 adulterated, outdated or misbranded, the [board] shall direct the immediate removal of the tag or  
339 other marking.

340 (4) If the court finds that a detained or embargoed drug or device is adulterated,  
341 outdated or misbranded, that drug or device, after entry of the decree, shall be destroyed at the  
342 expense of the owner under the supervision of a [board] representative and all court costs and  
343 fees, storage and other proper expenses shall be borne by the owner of that drug or device. When  
344 the outdateding, adulteration or misbranding can be corrected by proper labeling or processing of  
345 the drug or device, the court, after entry of the decree and after the costs, fees and expenses have  
346 been paid and a good and sufficient bond has been posted, may direct that the drug or device be  
347 delivered to the owner thereof for labeling or processing under the supervision of a board  
348 representative. Expense of that supervision shall be paid by the owner. The bond shall be  
349 returned to the owner of the drug or device on representation to the court by the [board] that the  
350 drug or device is no longer in violation of the embargo and the expense of supervision has been  
351 paid.

352 d. Except as otherwise provided to the contrary, the [board] shall exercise all of its  
353 duties, powers and authority in accordance with the [insert citation].

354

355 Section 11. [*Licensure Required For Pharmacist.*]

356 a. Except as otherwise provided in this Act, it shall be unlawful for any individual to  
357 engage in the practice of pharmacy unless currently licensed to practice under the provisions of  
358 this Act.

359 b. The provisions of this Act shall not apply to the sale of any drug by a manufacturer or  
360 wholesaler or pharmacy to each other or to a physician, dentist, veterinarian or other person  
361 licensed to prescribe such drugs in their professional practice.

362 c. Practitioners authorized under the laws of this State to compound drugs and to  
363 dispense drugs directly to their patients in the practice of their respective professions shall meet  
364 the standards established by their respective licensing boards with respect to storage, handling,  
365 security, counseling, labeling, packing and record keeping requirements for the dispensing of  
366 drugs, or if no such standards exist, the same storage, handling, security, counseling, labeling,  
367 packaging and record keeping requirements for the dispensing of drugs applicable to  
368 pharmacists.



369

370 Section 12. [*Application For License; Requirements.*] To obtain a license to engage in  
371 the practice of pharmacy, the applicant shall:

372 (1) Have submitted a written application in the form prescribed by the [board];

373 (2) Have attained the age of [18 years];

374 (3) Be of good moral character;

375 (4) Have graduated and received a professional degree from a college or school of  
376 pharmacy that has been approved by the [board];

377 (5) Have completed an internship or other program that has been approved by the  
378 [board], or demonstrated to the [board's] satisfaction experience in the practice of pharmacy  
379 which meets or exceeds the minimum internship requirements of the [board];

380 (6) Have successfully passed an examination or examinations as determined by  
381 the [board]; and

382 (7) Have paid the fees specified by the [board] for the examination and any related  
383 materials, and have paid for the issuance of the license.

384

385 Section 13. [*Examination for Licensure.*] The examination for licensure shall measure the  
386 competence of the applicant to engage in the practice of pharmacy. The [board] may employ,  
387 cooperate and contract with any organization or consultant in the preparation and grading of an  
388 examination, but shall retain the sole discretion and responsibility for determining which  
389 applicants have successfully passed the examination.

390

391 Section 14. [*Practical Experience, Requirements.*]

392 a. All applicants for licensure by examination shall obtain practical experience in the  
393 practice of pharmacy under terms and conditions determined by the [board].

394 b. The [board] may establish licensure requirements for interns and standards for  
395 internship, or any other experiential program necessary to qualify an applicant for the licensure  
396 examination, and shall also determine the qualifications of preceptors used in practical  
397 experience programs.

398

399 Section 15. [*Licensure for Pharmacist Currently Licensed in Another Jurisdiction.*]

400 a. In order for a pharmacist currently licensed in another jurisdiction to obtain a license  
401 as a pharmacist by license transfer in this State, an applicant shall:

402 (1) Have submitted a written application in the form prescribed by the [board];

403 (2) Have attained the age of [18 years];

404 (3) Have good moral character;

405 (4) Have engaged in the practice of pharmacy for a period of at least [1,000 hours]  
406 within the last [two years] or have met, immediately prior to application, the internship  
407 requirements of this State within the [one-year] period immediately preceding the date of  
408 application;

409 (5) Have presented to the [board] proof of initial licensure by examination and  
410 proof that the license is in good standing;

411 (6) Have presented to the [board] proof that any other license granted to the  
412 applicant by any other state has not been suspended, revoked or otherwise restricted for any  
413 reason except nonrenewal or for the failure to obtain the required continuing education credits in  
414 any state where the applicant is currently licensed but not engaged in the practice of pharmacy;

415 (7) Have paid the fees specified by the [board];

416 (8) Have graduated and received a professional degree from a college or school of  
417 pharmacy approved by the [board]; and

418 (9) Have met any other requirements as established by the [board] by regulation.  
419 b. No applicant shall be eligible for license transfer unless the applicant holds a current  
420 valid license in a state that grants licensure transfer to pharmacists duly licensed by examination  
421 in this State.

422 c. In order for a pharmacist applicant with a pharmacy degree from a foreign country or a  
423 college of pharmacy not approved by the [board] to obtain a license as a pharmacist, that  
424 applicant shall meet those requirements as established by the [board] by regulation.  
425

426 Section 16. [*Continuing Pharmacy Education.*]

427 a. The [board] shall require each person registered as a pharmacist, as a condition for  
428 [biennial] renewal certification, to complete continuing pharmacy education during each  
429 [biennial] period immediately preceding the date of renewal and submit proof thereof to the  
430 [board].

431 b. The [board] shall:

432 (1) Establish standards for continuing pharmacy education, including the number  
433 of credits, the subject matter and content of courses of study, the selection of instructors and the  
434 type of continuing education credits required of a registered pharmacist as a condition of  
435 [biennial] registration;

436 (2) Approve educational programs offering credit towards continuing pharmacy  
437 education requirements; and

438 (3) Approve other equivalent educational programs, including, but not limited to,  
439 home study courses, and establish procedures for the issuance of credit upon satisfactory proof of  
440 the completion of these programs. In the case of continuing education courses and programs,  
441 each hour of instruction shall be equivalent to [one credit].

442 c. (1) The [board] shall only approve programs that are provided on a  
443 nondiscriminatory basis. The [board] shall permit any pharmacy association or organization  
444 offering a continuing pharmacy education program approved by the [board] pursuant to  
445 subsection b. of this section to impose a reasonable differential in registration fees for courses  
446 upon registered pharmacists who are not members of that pharmacy association or organization.  
447 The [board] may approve programs held within or outside the State.

448 (2) In no event shall the [board] grant credits for, or approve as, a component of a  
449 continuing education program:

450 (a) participation in a routine business portion of a meeting of a pharmacy  
451 association or organization; or

452 (b) any presentation that is offered to sell a product or promote a business  
453 enterprise.

454 d. (1) The [board] may, in its discretion, waive requirements for continuing  
455 education on an individual basis for reasons of hardship, such as illness or disability, retirement  
456 of the registration certificate, or any other good cause.

457 (2) The [board] shall not require completion of continuing education credits for  
458 an initial renewal of registration.

459 (3) If a pharmacist completes a number of continuing education credit hours in  
460 excess of the number required for a biennial period, the [board] may allow, by rule or regulation,  
461 credits to be carried over to satisfy the pharmacist's continuing education requirement for the  
462 next [biennial] renewal period, but shall not be applicable thereafter.  
463

464 Section 17. [*Use of {State} Prescription Blanks.*]

465 a. A practitioner practicing in this State shall use non-reproducible, non-erasable safety  
466 paper [state] Prescription Blanks bearing that practitioner's license number whenever the

467 practitioner issues prescriptions for controlled dangerous substances, prescription legend drugs  
468 or other prescription items. The prescription blanks shall be secured from a vendor approved by  
469 the [Division of Consumer Affairs in the Department of Law and Public Safety].

470 b. A licensed practitioner practicing in this State shall maintain a record of the receipt of  
471 [state] Prescription Blanks. The practitioner shall notify the [Office of Drug Control in the  
472 Division of Consumer Affairs] as soon as possible but no later than [72 hours] of being made  
473 aware that any [state] Prescription Blank in the practitioner's possession has been stolen. Upon  
474 receipt of notification, the [Office of Drug Control] shall take appropriate action, including  
475 notification to the [Department of Human Services] and the [Attorney General].

476

477 Section 18. [*Health Care Facility Prescriptions.*]

478 a. Prescriptions issued by a health care facility licensed pursuant to [insert citation] shall  
479 be written on non-reproducible, non-erasable safety paper [state] Prescription Blanks. The  
480 prescription blanks shall be secured from a vendor approved by the [Division of Consumer  
481 Affairs in the Department of Law and Public Safety]. The [state] Prescription Blanks shall bear  
482 the unique provider number assigned to that health care facility for the issuing of prescriptions  
483 for controlled dangerous substances, prescription legend drugs or other prescription items.

484 b. A health care facility shall maintain a record of the receipt of [state] Prescription  
485 Blanks. The health care facility shall notify the [Office of Drug Control in the Division of  
486 Consumer Affairs] as soon as possible but no later than [72 hours] of being made aware that any  
487 [state] Prescription Blank in the facility's possession has been stolen. Upon receipt of  
488 notification, the [Office of Drug Control] shall take appropriate action including notification to  
489 the [Department of Human Services] and the [Attorney General].

490

491 Section 19. [*Requirements for Prescription to be Filled.*] A prescription issued by a  
492 practitioner or health care facility licensed in [this State] shall not be filled by a pharmacist  
493 unless the prescription is issued on a [state] Prescription Blank bearing the practitioner's license  
494 number or the unique provider number assigned to a health care facility.

495

496 Section 20. [*Transmission of Prescription by Telephone, Electronic Means, CDS*  
497 *Requirements.*]

498 a. Nothing contained in this Act shall preclude a practitioner from transmitting to a  
499 pharmacist by telephone or electronic means a prescription, as otherwise authorized by law, if  
500 that practitioner provides the practitioner's Drug Enforcement Administration registration  
501 number and the practitioner's license number, or any other federally identified number, as  
502 appropriate, to the pharmacist at the time the practitioner transmits the prescription.

503 b. Except as may be otherwise permitted by law, no prescription for any Schedule II  
504 controlled dangerous substance shall be given or transmitted to pharmacists, in any other  
505 manner, than in writing signed by the practitioner giving or transmitting the same, nor shall such  
506 prescription be renewed or refilled. The requirement in this subsection that a prescription for any  
507 controlled dangerous substance be given or transmitted to pharmacists in writing signed by the  
508 practitioner shall not apply to a prescription for a Schedule II drug if that prescription is  
509 transmitted or prepared in compliance with federal and State regulations.

510

511 Section 21. [*Format for {State} Prescription Blanks.*] The [Division of Consumer Affairs  
512 in the Department of Law and Public Safety] shall establish the format for uniform, non-  
513 reproducible, non-erasable safety paper prescription blanks, to be known as [state] Prescription  
514 Blanks, which format shall include an identifiable logo or symbol that will appear on all  
515 prescription blanks. The [division] shall approve a sufficient number of vendors to ensure

516 production of an adequate supply of [state] Prescription Blanks for practitioners and health care  
517 facilities statewide.

518

519 Section 22. [*Different Dosage Form, Conditions.*] A pharmacist may dispense a  
520 prescription in a different dosage form than originally prescribed if the pharmacist notifies the  
521 prescriber no later than [48 hours] following the dispensing of the prescription, provided the  
522 dosage form dispensed has the appropriate drug release rate.

523

524 Section 23. [*Requirements for Collaborative Practice.*]

525 a. In establishing requirements for pharmacists to engage in collaborative practice as  
526 provided in paragraph (4) of subsection a. of section 10 of this Act, the [board] shall include in  
527 these requirements, but not be limited to, provisions that any written protocol between a  
528 physician and pharmacist:

529 (1) is agreed to by both the physician and the pharmacist with the consent of the  
530 patient;

531 (2) identifies, by name and title, each physician and each pharmacist who is  
532 permitted to participate in a patient's collaborative drug therapy management;

533 (3) specifies the functions and responsibilities the pharmacist will be performing;

534 (4) is available at the practice sites of the pharmacist and physician and made  
535 available at each site to the patient;

536 (5) is initiated and utilized at the sole discretion of the physician for a specific  
537 patient;

538 (6) may be terminated at any time by either party by written documentation;

539 (7) establishes when physician notification is required, the physician chart update  
540 interval, and an appropriate time frame within which the pharmacist must notify the physician of  
541 any change in dose, duration or frequency of medication prescribed;

542 (8) remains in effect for a period not to exceed [two years] upon the conclusion of  
543 which, or sooner, the parties shall review the protocol and make a determination as to its  
544 renewal, modification or termination; and

545 (9) establish the means by which the patient will be advised of the right to elect to  
546 participate in and withdraw from the collaborative drug therapy management.

547

548 Section 24. [*Collaborative Drug Therapy Management.*]

549 a. Each collaborative drug therapy management shall be between a single patient's  
550 specific physician and the patient's pharmacist or pharmacy and address that patient's specific  
551 condition, disease or diseases.

552 b. No collaborative drug therapy management shall include, without the prior consent of  
553 the patient and the patient's physician who has signed the protocol, therapeutic interchange at the  
554 time of dispensing, provided that written confirmation of this prior consent, which may be by  
555 electronic means, shall be obtained pursuant to record keeping guidelines to be established by  
556 regulation jointly promulgated by the [board] and the [State Board of Medical Examiners].

557

558 Section 25. [*Administration of Prescription Medication Directly to Patient,*  
559 *Immunizations.*]

560 a. No pharmacist shall administer a prescription medication directly to a patient without  
561 appropriate education or certification, as determined by the [board] in accordance with the  
562 requirements set forth in the rules jointly promulgated by the [board] and the [State Board of  
563 Medical Examiners]. Such medication shall only be for the treatment of a disease for which a  
564 nationally certified program is in effect, or as determined by the [board], and only if utilized for

565 the treatment of that disease for which the medication is prescribed or indicated or for which the  
566 collaborative drug therapy management permits.

567 b. Notwithstanding any law, rule or regulation to the contrary, other than for pediatric  
568 immunizations, a pharmacist may administer drugs in immunization programs and programs  
569 sponsored by governmental agencies that are not patient specific provided the pharmacist is  
570 appropriately educated and qualified, as determined by the [board] in accordance with the  
571 requirements set forth in the rules jointly promulgated by the [board] and the [State Board of  
572 Medical Examiners].

573

574 Section 26. [*Inapplicability Relative to Collaborative Drug Therapy Management in*  
575 *Hospitals.*] The provisions of this Act regulating collaborative drug therapy management shall  
576 not apply to any pharmacist practicing in a hospital, provided that prescribing within these  
577 institutions takes place under the guidance of a pharmacy and therapeutics committee in  
578 accordance with procedures as determined by regulations jointly promulgated by the [board] and  
579 the [State Board of Medical Examiners].

580

581 Section 27. [*Refusal of Application for Examination, Suspension, Revocation of*  
582 *Certificate; Procedure.*]

583 a. In addition to the provisions of [insert citation], the [board] may refuse an application  
584 for examination or may suspend or revoke the certificate of a licensed pharmacist upon proof  
585 satisfactory to the [board] that such licensed pharmacist is guilty of grossly unprofessional  
586 conduct and the following acts are hereby declared to constitute grossly unprofessional conduct  
587 for the purpose of this Act:

588 (1) Paying rebates or entering into an agreement for payment of rebates to any  
589 physician, dentist or other person for the recommending of the services of any person.

590 (2) The providing or causing to be provided to a physician, dentist, veterinarian  
591 or other person authorized to prescribe, prescription blanks or forms bearing the pharmacist's or  
592 pharmacy's name, address or other means of identification.

593 (3) The claiming of professional superiority in the compounding or filling of  
594 prescriptions or in any manner implying professional superiority which may reduce public  
595 confidence in the ability, character or integrity of other pharmacists.

596 (4) Fostering the interest of one group of patients at the expense of another  
597 which compromises the quality or extent of professional services or facilities made available.

598 (5) The distribution of premiums or rebates of any kind whatsoever in  
599 connection with the sale of drugs and medications provided, however, that trading stamps and  
600 similar devices shall not be considered to be rebates for the purposes of this act and provided  
601 further that discounts, premiums and rebates may be provided in connection with the sale of  
602 drugs and medications to any person who is [60 years] of age or older.

603 (6) Advertising of prescription drug prices in a manner inconsistent with rules  
604 and regulations promulgated by the [Director of the Division of Consumer Affairs], except that  
605 no advertising of any drug or substance shall be authorized unless the [Commissioner of Health  
606 and Senior Services] shall have determined that the advertising is not harmful to public health,  
607 safety and welfare.

608 (7) Engaging in activities beyond the scope of a collaborative drug therapy  
609 management agreement.

610 b. Before a certificate shall be refused, suspended or revoked, the accused person shall be  
611 furnished with a copy of the complaint and given a hearing before the [board]. Any person  
612 whose certificate is so suspended or revoked shall be deemed an unlicensed person during the  
613 period of such suspension or revocation, and as those shall be subject to the penalties prescribed

614 in this act, but that person may, at the discretion of the [board], have his certificate reinstated at  
615 any time without an examination, upon application to the [board]. Any person to whom a  
616 certificate shall be denied by the board or whose certificate shall be suspended or revoked by the  
617 [board] shall have the right to review that action by appeal to the [Appellate Division of the  
618 Superior Court] in lieu of prerogative writ.

619

620 Section 28. [*Drug Utilization Review, Requirements.*]

621 a. A pharmacist shall conduct a drug utilization review before each new medication is  
622 dispensed or delivered to a patient.

623 b. A pharmacist shall conduct a prospective drug utilization review in accordance with  
624 the provisions of this section before refilling a prescription or medication order to the extent he  
625 deems appropriate in his professional judgment.

626 c. A pharmacist shall exercise independent professional judgment as to whether or not to  
627 dispense or refill a prescription or medication order. In determining to dispense or refill a  
628 prescription or medication order, the decision of the pharmacist shall not be arbitrary but shall be  
629 based on professional experience, knowledge or available reference materials.

630

631 Section 29. [*Provision of Counseling on New Prescriptions.*] A pharmacist or his  
632 designee shall offer to provide counseling to any person who presents a new prescription in a  
633 manner as determined pursuant to criteria established by the [board].

634

635 Section 30. [*Patient Profile System.*]

636 a. A patient profile system shall be maintained by all pharmacies for persons for whom  
637 medications are dispensed. The patient profile record system shall enable the dispensing  
638 pharmacist to identify previously dispensed medication at the time a prescription is presented for  
639 dispensing.

640 b. The following information generated or transferred to the individual pharmacy practice  
641 site shall be recorded in the patient profile system:

642 (1) The family and the first name of the person for whom the medication is  
643 intended (the patient);

644 (2) The street address and telephone number of the patient;

645 (3) Indication of the patient's age, birth date or age group (infant, child, adult) and  
646 gender;

647 (4) The height, weight and other patient specific criteria for those medications that  
648 are height or weight dose dependent;

649 (5) The original or refill date the medication is dispensed and the initials of the  
650 dispensing pharmacist, if those initials and date are not recorded on the original prescription or in  
651 any other record approved by the board;

652 (6) The number or designation identifying the prescription;

653 (7) The practitioner's name;

654 (8) The name, strength and quantity of the drug dispensed;

655 (9) The individual history, if significant, including known allergies and drug  
656 reactions, known diagnosed disease states and a comprehensive list of medications and relevant  
657 devices; and

658 (10) Any additional comments relevant to the patient's drug use, which may  
659 include any failure to accept the pharmacist's offer to counsel.

660 c. The information obtained shall be recorded in the patient's manual or electronic  
661 profile, or in the prescription signature log, or in any other system of records, and may be  
662 considered by the pharmacist in the exercise of his professional judgment concerning both the

663 offer to counsel and content of counseling. The absence of any record of a failure to accept the  
664 pharmacist's offer to counsel shall be presumed to signify that the offer was accepted and that  
665 the counseling was provided.

666

667 Section 31. [*Issuance of Permit for Pharmacy Practice Sites.*]

668 a. All pharmacy practice sites in this State, which engage in the practice of pharmacy in  
669 [this State], shall be issued a permit by the [board], and shall annually renew their permit with  
670 the [board]. If operations are conducted at more than one location, each location shall be issued a  
671 permit by the [board] for the dispensing of medicine.

672 b. The [board] may determine by rule or regulation the permit classifications of all  
673 pharmacy practice sites issued a permit under this Act, and establish minimum standards for  
674 pharmacy practice sites.

675 c. The [board] shall establish by rule or regulation the criteria which each site shall meet  
676 to qualify for a permit in each classification. The [board] may issue permits with varying  
677 restrictions to pharmacy practice sites if the [board] deems it necessary.

678 d. Each holder of a pharmacy practice site permit shall ensure that a licensed pharmacist  
679 be immediately available on the premises to provide pharmacy services at all times the pharmacy  
680 practice site is open.

681 e. Each pharmacy practice site shall have a pharmacist-in-charge. The pharmacist-in-  
682 charge and the owner of a pharmacy practice site shall be responsible for any violation of any  
683 laws or regulations pertaining to the practice of pharmacy.

684 f. The [board] may enter into agreements with other states or with third parties for the  
685 purpose of exchanging information concerning the granting of permits and the inspection of  
686 pharmacy practice sites located in this State and those located outside this State.

687 g. The [board] may deny, suspend, revoke, restrict or refuse to renew a permit for a  
688 pharmacy practice site that does not comply with the provisions of this act or any rule or  
689 regulation promulgated pursuant to this Act.

690

691 Section 32. [*Permit Application Procedures.*]

692 a. The [board] shall specify by rule or regulation the permit application procedures to be  
693 followed, including, but not limited to, the specification of forms to be used, the time and place  
694 the application is to be made and the fees to be charged.

695 b. Applicants for a permit to operate a pharmacy practice site within this State shall file  
696 with the board a verified application containing the information that the board requires of the  
697 applicant relative to the qualifications for the specific permit.

698 c. The [board] shall specify, by rule or regulation, minimum standards for any pharmacy  
699 practice site within this State. Pharmacy practice sites located in [this State] shall be operated at  
700 all times under the immediate supervision of a pharmacist licensed to practice in this State.

701 d. Permits issued by the [board] pursuant to this Act shall not be transferable or  
702 assignable without the approval of the [board].

703

704 Section 33. [*Licensure Required for Use of Certain Terms.*] No person shall carry on,  
705 conduct or transact business under a name which contains as a part thereof the words  
706 "pharmacist," "pharmacy," "apothecary," "apothecary shop," "druggist," "drug" or any word or  
707 words of similar or like import, or in any manner by advertisement, circular, poster, sign or  
708 otherwise describe or refer to the place of business by the terms "pharmacy," "apothecary,"  
709 "apothecary shop," "chemist's shop," "drug store," "drugs" or any word or words of similar or  
710 like import unless the place of business is a currently licensed pharmacy practice site operated or  
711 managed at all times by a pharmacist.

712

713 Section 34. [*Sale of Non-Prescription Drugs, Devices Unaffected.*] This Act shall not  
714 prohibit, restrict or otherwise interfere with the sale of non-prescription drugs and devices at  
715 places other than a pharmacy practice site or by persons in this State who are not licensed  
716 pharmacists.

717

718 Section 35. [*Registration of Out-Of-State Pharmacies; Requirements.*]

719 a. Any pharmacy located in another state which ships, mails, distributes or delivers in any  
720 manner, legend drugs or devices pursuant to a prescription into this State, shall register with the  
721 [board] and provide the [board] with the following information:

722 (1) The location, names and titles of all principal corporate officers of the  
723 pharmacy. A report containing this information shall be made on an annual basis and within [30  
724 days] after any change of office or corporate officer; and

725 (2) That it complies with all lawful directions and requests for information from  
726 the regulatory or licensing agency of the state in which it is licensed as well as with all requests  
727 for information made by the [board] pursuant to this section. As a prerequisite to registering with  
728 the [board], the pharmacy shall submit a copy of the most recent inspection report resulting from  
729 an inspection conducted by the regulatory or licensing agency of the state in which it is located.  
730 The annual registration fee shall be established by the [board] and shall not exceed [\$500]  
731 annually.

732 b. Any pharmacy subject to this section shall, during its regular hours of operation, but  
733 not less than [six days per week], and for a minimum of [40 hours per week], provide a toll-free  
734 telephone service to facilitate communication between patients in this State and a pharmacist at  
735 a pharmacy who has access to the patient's records. This toll-free number shall be disclosed on a  
736 label affixed to each container of drugs dispensed to patients in this State.

737

738 Section 36. [*Report of Certain Occurrences.*]

739 a. All licensed pharmacy practice sites shall report to the [board] the occurrences of any  
740 of the following:

741 (1) Closing of the pharmacy practice site;

742 (2) Change of ownership, location, interior site design, permit classification or  
743 pharmacist-in-charge of the pharmacy practice site;

744 (3) Any significant theft or loss of legend drugs or devices;

745 (4) Disasters, accidents, any theft, destruction or loss of records required to be  
746 maintained by State or federal law;

747 (5) Any pharmacy malpractice liability insurance claim settlement, judgment or  
748 arbitration award in excess of [\$10,000] to which an owner, an employee of, or the pharmacy  
749 practice site itself is a party; and

750 (6) Any and all other matters and occurrences as the [board] may require by rule  
751 or regulation.

752 b. The manner, time and content of the notification shall be prescribed by rule or  
753 regulation by the [board].

754

755 Section 37. [*Permit Required for Operation of Pharmacy Practice Site.*]

756 a. No pharmacy practice site shall operate until it has been issued a permit by the  
757 [board].

758 b. The [board] may suspend, revoke, deny, restrict or refuse to renew the permit of any  
759 pharmacy practice site on any of the following grounds:



- 760 (1) Findings by the [board] that any conduct of the permit holder or applicant  
761 violates any federal, State or local laws or regulations relating to the practice of pharmacy;  
762 (2) A conviction of the permit holder or applicant under federal, State or local  
763 laws for a crime of moral turpitude or a crime that relates adversely to the practice of pharmacy;  
764 (3) Materially false or fraudulent information contained within any application  
765 made to the board or in any application relating to drug or device prescribing, dispensing or  
766 administration;  
767 (4) Suspension or revocation by federal, State or local government of any license  
768 or permit relating to the practice of pharmacy currently or previously held by the applicant or  
769 permit holder;  
770 (5) Utilizing a permit to obtain remuneration by fraud, misrepresentation or  
771 deception;  
772 (6) Dealing with drugs or devices that are known or should have been known as  
773 stolen drugs or devices;  
774 (7) Purchasing or receiving of a drug or device by a permit holder or for use at a  
775 pharmacy practice site from a source that is not licensed under the laws of the State, except  
776 where otherwise provided;  
777 (8) Intensive and ongoing failure to provide additional personnel, automation and  
778 technology as is necessary to ensure that the licensed pharmacist on duty has sufficient time to  
779 utilize the professional's knowledge and training and to competently perform the functions of a  
780 licensed pharmacist as required by law; or  
781 (9) Violation of any of the provisions of the [state controlled substance Act] by  
782 the applicant, permit holder or occurring at the pharmacy practice site; or  
783 c. Reinstatement of a permit that has been suspended or restricted by the [board] may be  
784 granted in accordance with the procedures specified by the [board].  
785

786 Section 38. [*Compliance With Federal Law, Standards.*] Pharmacists and pharmacies  
787 shall comply with the provisions of the federal Standards of Practice of Individually Identifiable  
788 Health Information, 45 C.F.R. Parts 160 and 164.  
789

790 Section 39. [*Immunity from Civil Damages for Reports of Alleged Misconduct.*] A person  
791 who in good faith and without malice provides to the [board] any information concerning any act  
792 by a pharmacist licensed by the [board] which the person has reasonable cause to believe  
793 involves misconduct that may be subject to disciplinary action by the [board], or any information  
794 relating to such conduct requested by the [board] in the exercise of its statutory responsibilities  
795 or which may be required by statute, shall not be liable for civil damages in any cause of action  
796 arising out of the provision of such information or services.  
797

798 Section 40. [*Currently Licensed Pharmacists, Practice Sites.*]

799 a. Any person who is licensed in this State as a pharmacist on the effective date of this  
800 act may continue to practice under his current license until its expiration, and to obtain a license  
801 under this Act without examination upon payment of a fee.

802 b. Any site with a permit in this State as a pharmacy practice site on the effective date of  
803 this Act may continue to operate under its current permit until its expiration.  
804

805 Section 41. [*Prior Regulations Unaffected.*] This Act shall not affect the orders, rules and  
806 regulations regarding the practice of pharmacy made or promulgated by the [board] created  
807 pursuant to [insert citation] prior to the effective date of this Act.  
808

809 Section 42. [*Pharmacy Technicians, Conditions.*]  
810 a. Pharmacy technicians may assist a licensed pharmacist in performing the following  
811 tasks:  
812 (1) Retrieval of prescription files, patient files and profiles and other records, as  
813 determined by the [board], pertaining to the practice of pharmacy;  
814 (2) Data entry;  
815 (3) Label preparation; and  
816 (4) Counting, weighing, measuring, pouring and compounding of prescription  
817 medication or stock legend drugs and controlled substances, including the filling of an automated  
818 medication system.  
819 b. Pharmacy technicians may accept authorization from a patient for a prescription refill,  
820 or from a physician or the physician's agent for a prescription renewal, provided that the  
821 prescription remains unchanged. As used in this section, "prescription refill" means the  
822 dispensing of medications pursuant to a prescriber's authorization provided on the original  
823 prescription and "prescription renewal" means the dispensing of medications pursuant to  
824 a practitioner's authorization to fill an existing prescription that has no refills remaining.  
825 c. Pharmacy technicians shall not:  
826 (1) Receive new verbal prescriptions;  
827 (2) Interpret a prescription or medication order for therapeutic acceptability and  
828 appropriateness;  
829 (3) Verify dosage and directions;  
830 (4) Engage in prospective drug review;  
831 (5) Provide patient counseling;  
832 (6) Monitor prescription usage;  
833 (7) Override computer alerts without first notifying the pharmacist;  
834 (8) Transfer prescriptions from one pharmacy to another pharmacy; or  
835 (9) Violate patient confidentiality.  
836 d. Except as provided in subsection e. of this section, a pharmacist shall not supervise  
837 more than [two] pharmacy technicians.  
838 e. A pharmacy that wishes to employ a licensed pharmacist to pharmacy technician ratio  
839 greater than established in accordance with subsection d. of this section, shall:  
840 (1) Establish written job descriptions, task protocols and policies and procedures  
841 that pertain to the duties performed by the pharmacy technician;  
842 (2) Ensure and document that each pharmacy technician pass the National  
843 Pharmacy Technician Certification Examination or a [board] approved certification program and  
844 fulfill the requirements to maintain this status, or complete a program which includes a testing  
845 component and which has been approved by the [board] as satisfying the criteria as set forth in  
846 subsection f. of this section;  
847 (3) Ensure that each pharmacy technician is knowledgeable in the established job  
848 descriptions, task protocols and policies and procedures in the pharmacy setting in which the  
849 technician is to perform his duties;  
850 (4) Ensure that the duties assigned to any pharmacy technician do not exceed the  
851 established job descriptions, task protocols and policies and procedures;  
852 (5) Ensure that each pharmacy technician receives in-service training before the  
853 pharmacy technician assumes his responsibilities and maintain documentation thereof;  
854 (6) Require and maintain on site a signed patient confidentiality statement from  
855 each technician;  
856 (7) Provide immediate personal supervision; and

857 (8) Provide the [board], upon request, with a copy of the established job  
858 descriptions, task protocols and policies and procedures for all pharmacy technician duties.

859 f. If the pharmacist to pharmacy technician ratio is greater than the ratio established in  
860 accordance with the provisions of subsection d. of this section, the pharmacy shall maintain a  
861 policy and procedure manual with regard to pharmacy technicians, which shall include the  
862 following:

- 863 (1) Supervision by a pharmacist;
- 864 (2) Confidentiality safeguards of patient information;
- 865 (3) Minimum qualifications;
- 866 (4) Documentation of in-service education or ongoing training and demonstration  
867 of competency, specific to practice site and job function;
- 868 (5) General duties and responsibilities of pharmacy technicians;
- 869 (6) Retrieval of prescription files, patient files, patient profile information and  
870 other records pertaining to the practice of pharmacy;
- 871 (7) Functions related to prescription processing;
- 872 (8) Functions related to prescription legend drug and controlled dangerous  
873 substance ordering and inventory control;
- 874 (9) Prescription refill and renewal authorization;
- 875 (10) Procedures dealing with documentation and records required for controlled  
876 dangerous substance and prescription legend drugs;
- 877 (11) Procedures dealing with medication errors;
- 878 (12) Pharmacy technician functions related to automated systems;
- 879 (13) Functions that may not be performed by pharmacy technicians; and
- 880 (14) A form signed by the pharmacy technician which verifies that the manual has  
881 been reviewed by the technician.

882 g. The pharmacist in charge shall review the policy and procedure manual at least every  
883 [two years] and, if necessary, amend the manual as needed. Documentation of the review shall be  
884 made available to the [board] upon request.

885 h. Pharmacy technicians shall wear an identification tag, which shall include at least their  
886 first name, the first initial of their last name and title.

887 i. On pharmacy permit renewal applications, the pharmacy shall list the name and address  
888 of all pharmacy technicians which it currently employs.

889 j. When pharmacy technicians are engaged in any activities permitted in accordance with  
890 the provisions of this section, the licensed pharmacists on site shall be responsible for these  
891 activities.

892  
893 Section 43. [*Severability.*] [Insert severability clause.]

894  
895 Section 44. [*Repealer.*] [Insert repealer clause.]

896  
897 Section 45. [*Effective Date.*] [Insert effective date.]